An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection
NCT ID: NCT01924793
Last Updated: 2017-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
23 participants
INTERVENTIONAL
2013-08-31
2017-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
All subjects will have additional PK and Immunogenicity blood samples collected.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
NCT03808922
Safety Study of a Human Metapneumovirus Challenge Virus in Healthy Adults
NCT01109329
Evaluation of the Safety and Immunogenicity of a Live Attenuated Human Metapneumovirus Vaccine
NCT01255410
A Study to Investigate the Safety and Tolerability of Single and Repeat Doses of PC786
NCT03236233
A Study of EDP-323 in Healthy Subjects
NCT05587478
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Eligible immunocompromised patients positively diagnosed with PIV infection will receive DAS181 by DPI or Nebulized formulation.
DPI: 10 mg DAS181 will be administered for seven (7) consecutive days for up to a total cumulative dose of 70mg.
Nebulized: DAS181 F02 formulation in solution will be administered for seven (7) consecutive days for up to a total cumulative dose of 28.9 mg.
Assessment of viral shedding and viral resistance testing will be performed on collected viral load samples. Blood samples will be obtained to evaluate safety at each scheduled visit.
Routine safety monitoring (including Adverse Event (AE) reporting, clinical laboratory tests, vital signs, electrocardiogram (ECG) and )2 levels) will be conducted in all subjects. A final safety assessment will occur at Day 28 (+/- 2 days) after enrollment/first dose of study drug. Survival, diary cards, and quality of life will be collected at Day 60 and 90. PK will be collected at each visit on all subjects from baseline/visit 2 to visit 11/Day 28. Immunogenicity samples will be collected at selected time points in all subjects.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Formulation of DAS181-F02 Dry Powder in Bulk
The DAS181-F02 nebulized formulation includes 10mL of normal saline to prepare a liquid solution referred to as DAS181-F02 nebulized.
Dry Powder Inhaled Dose:
Non-ventilated subjects, capable of using a cyclohaler, will be treated by Dry Powder Inhalation. Each subject will receive a targeted daily dose of 10mg for 7 days for a total of 70mg of DAS181-F02. If a subject requires ventilation, the subject will be allowed to continue dosing following the Nebulized formulation instruction.
DAS181-F02 Dry Powder in Bulk
Administered via DPI
Nebulized Formulation Inhaled Dose
Subjects unable to use the Dry Powder Inhaler (as determined by site Investigator) on continuous positive airway pressure (CPAP), Bi-level positive airway pressure (BIPAP) or requiring mechanical ventilation will be treated by Nebulized formulation. The subject will remain on the nebulized formulation for the duration of the study regardless of ventilation status. DAS-F02 10 mg will be utilized to prepare the nebulized solution per the Study Reference Manual.
Multiple methods (T piece, face mask, direct to ET tube) will be allowed for the nebulized dose administration. Detailed specification for nebulized dose administration will be defined in the Study Reference Manual.
DAS181-F02 Nebulized Formulation Inhaled Dose
Administered via Nebulizer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DAS181-F02 Dry Powder in Bulk
Administered via DPI
DAS181-F02 Nebulized Formulation Inhaled Dose
Administered via Nebulizer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Able to provide informed consent or child assent with parental consent
3. Immunocompromised, as defined by one of the following:
* Allogeneic hematopoietic cell transplantation (HCT)
* Lung or lung-heart transplantation
* Patients treated with chemotherapy for hematologic malignancies or autologous HCT
4. Confirmed Parainfluenza virus by nasopharyngeal swab or tracheal aspirate for one of the following:
* Respiratory virus panel
* DFA
* Qualitative/quantitative RT-PCR test for parainfluenza virus performed at the local laboratory (a confirmatory PCR test will be done at the central lab but is not required to start the patient on study).
5. Female subjects of child-bearing potential who are capable of conception must be:
post-menopausal (one year or greater without menses), surgically incapable of childbearing, or practicing two effective methods of birth control. Acceptable methods include intrauterine device, spermicide, barrier, male partner surgical sterilization and hormonal contraception. A female subject must agree to practice two acceptable methods of birth control during the 28 day study period. Abstinence is not an acceptable method of contraception. All reproductive female subjects must have a negative serum pregnancy test during the screening visit.
6. Male subjects must agree to use medically accepted form of contraception during the 28 day study period.
Exclusion Criteria
2. Any significant finding in the patient's medical history or physical examination that, in the opinion of the investigator, would affect patient safety, ability to use the dry powder inhaler or compliance with the dosing schedule.
3. Subjects currently treated with oral, aerosolized or IV ribavirin
4. Subjects taking any investigational drug used to research or treat PIV
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ansun Biopharma, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ron Moss, MD, CEO
Role: STUDY_CHAIR
Ansun Biopharma, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope
Duarte, California, United States
Children's Hospital of Orange County
Orange, California, United States
Stanford University Medical Center
Palo Alto, California, United States
University of Chicago
Chicago, Illinois, United States
Indiana Blood and Marrow Transplantation
Indianapolis, Indiana, United States
University of Kansas Cancer Center
Kansas City, Kansas, United States
John Hopkins University School of Medicine
Baltimore, Maryland, United States
Brigham & Women's Hospital
Boston, Massachusetts, United States
University of Minnesota, School of Medicine
Minneapolis, Minnesota, United States
Washington University School of Medicine
St Louis, Missouri, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York, United States
Weill Cornell Medical College-Peds
New York, New York, United States
Duke University
Durham, North Carolina, United States
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
University of Oklahoma
Oklahoma City, Oklahoma, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States
St. Jude Children's Research Hospital
Memphis, Tennessee, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Seattle Children's Hospital
Seattle, Washington, United States
Fred Hutchinson Cencer Research Center
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DAS181-2-06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.